Zydus Cadila Readies Injectables Push
Building Pipeline Amid Tepid US Growth Outlook, As Remdesivir Launches In India
Zydus Cadila expects domestic sales to improve and the US generics business to grow in “mid to high” single digits during FY21 after both saw a coronavirus-related hit in Q1. Meanwhile, approvals for a few biologics are expected, its COVID-19 vaccine candidate has just entered Phase II studies and the firm has just launched its Remdac version of remdesivir.
